ACHIEVE LIFE SCIENCES, INC. — Form 10-Q
Filed August 11, 2026 · analyzed by the Periodic Agent
10-Q
▼ Likely negative
significance 72/100
What the filing says
Richard Stewart's employment as CEO and Chairman of Achieve Pharma UK Limited and CEO of Achieve Life Sciences terminated effective May 8, 2026. Settlement agreement provides $1.39M in cash payments ($59,135 PTO + $76,875 bonus + $307,500 notice + $922,500 QT payment + $102,500 ex gratia), pension contribution of £30,000, legal fees up to £29,000, and equity acceleration (562,338 shares vest immediately; 75,000 PSUs continue vesting per original terms; 362,812 option shares remain subject to service). Andrew D. Goldberg, MD appointed as new CEO effective April 16, 2026, with base salary $665,000, target bonus 55%, and substantial equity package: 1% RSUs + 2% options + 6.5% performance PSUs (all on fully-diluted capitalization post-$150M minimum Qualified Financing), vesting over 4 years.
Why this rating
CEO departure + $1.4M severance costs ≈ 1.4% of $104M market cap; material leadership transition risk. New CEO hire with large equity grants and performance targets provides some mitigation. Both events meaningful for small-cap biotech company.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.